MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$164,043K
Net loss
attributable to redeemable...
-$2,512K
Net loss
-$166,555K
Product
$180,596K
Royalty
$9,500K
License And Service
$4,419K
Loss from operations
-$105,956K
Total other expense,
net
-$60,599K
Total revenues, net
$194,515K
Interest income
$6,246K
Other income, net
$4,253K
Total operating costs
and expenses
$300,471K
Noncash interest
expense on deferred...
$39,873K
Net loss from equity
method investments
-$18,283K
Interest expense
$12,942K
Selling, general and
administrative
$163,896K
Research and development
$126,636K
Total cost of revenues
$9,939K
Product
$7,732K
License Services And
Royalty
$2,207K
Back
Back
Income Statement
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)
source: myfinsight.com